Targeted-Release Budesonide in Primary IgA Nephropathy
In a phase 3, placebo-controlled trial of adults with primary immunoglobulin A (IgA) nephropathy, a formulation of targeted-release budesonide (Nefecon) reduced the decline in estimated
In a phase 3, placebo-controlled trial of adults with primary immunoglobulin A (IgA) nephropathy, a formulation of targeted-release budesonide (Nefecon) reduced the decline in estimated
Proton pump inhibitor (PPI) use may be an important and preventable source of fatigue and reduced health-related quality of life (HRQoL) in people who received
Eight independent predictors of kidney disease progression are identified using data for 41,204 patients with type 2 diabetes (T2D) from 4 Thrombolysis In Myocardial Infarction
In a post hoc comparison with insulin glargine in SURPASS-4 participants with type 2 diabetes and high cardiovascular risk, tirzepatide use slowed the decline of
In the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial, the use of dulaglutide (DU) was associated with a 25% reduced hazard
In people with diabetic kidney disease, canagliflozin reduced the relative risk of kidney events regardless of age or gender in a post-hoc analysis of results
Among patients with non-dialysis-dependent chronic kidney disease (CKD), hyperkalemia (serum potassium [sK+] > 5.0 mEq/L), and hyperphosphatemia, patiromer treatment was associated with reductions of [serum phosphorus (sP)]
The American Geriatrics Society has released its 2023 revision of the Beers Criteria with detailed discussions of anticoagulant use in adults aged 65 years or
Kidney transplant recipients (KTRs) may benefit from metformin therapy, according to a retrospective study from South Korea. The investigators sought to determine the value of
In the CREDENCE study, canagliflozin “consistently reduced the relative risk of kidney events in people with diabetic kidney disease in both sexes and across age